The FDA limited Dengvaxia to older children and teenagers living in endemic regions—and only if a diagnostic test confirms a prior dengue infection.
GSK's shingles vaccine Shingrix trounced expectations, but its HIV franchise is suffering on new competition from Gilead.
Sanofi has been among those hardest hit by diabetes pressure, and now, competition is hurting the prized asset from its $11.6 billion Bioverativ buy.
After supply constraints hindered Shingrix's launch last year, GSK is planning to expand adjuvant manufacturing operations in Montana.
If a new draft law goes into effect, companies that make or sell fake vaccines could get fines of up to 30 times the value of the goods involved.
An FDA panel gave Sanofi's Dengvaxia a mixed endorsement, voting down its use in people 17 and older.
Prosecutors in the Philippines have found probable cause to indict six Sanofi officials for its Dengvaxia rollout.
The FDA has issued guidance on continuous manufacturing and is allocating $58 million to move forward advanced manufacturing processes.
Here is some other vaccine news of note for the week.
CureVac is working on a printer to quickly create mRNA vaccine candidates against known pathogens and unknown diseases.